Arbutus to Participate in Upcoming Investor Conferences

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company will be participating in the following investor conferences:

• Chardan Inaugural Gene Therapy Conference, October 10, 2017, New York, and
• Jefferies Gene Technology Summit, October 12, 2017, New York.

About ArbutusArbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.

Contact Information

InvestorsAdam CutlerSenior Vice President, Corporate AffairsPhone: 604-419-3200 Email: [email protected]

Tiffany TolmieManager, Investor RelationsPhone: 604-419-3200 Email: [email protected]

MediaDavid SchullRusso PartnersPhone: 858-717-2310Email: [email protected]

Source: Arbutus Biopharma Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bucked Up® Launches Hunt: Orange Cream, a Limited-Edition Flavor Built to Fuel Your Hunt
• Micaela Wall Voted 2026 Winston-Salem Journal Readers' Choice Favorite Real Estate Agent
• Dr. Wael Sakr Scholarship Opens Applications for Aspiring Medical Students Nationwide